CSF3R mutations were previously identified as oncogenic, and the T618I mutation has been identified to truncate the cytoplasmic tail of CSF3R, which is similar to CSF3R mutations that have been observed to progress congenital neutropenia to AML [35]. This evidence concerns the gene CSF3R and severe congenital neutropenia.